SCHEMBL3982445

SCHEMBL3982445

CC(C)(C)OC(=O)N[C@@H](CS(=O)(=O)Cc1cnccn1)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 7/20 0.39
PPARG P37231 6/20 0.39
ITGB3 P05106 1/20 0.39
ITGA2B P08514 1/20 0.39
REN P00797 1/20 0.38
ACE P12821 1/20 0.38
MMP13 P45452 2/20 0.38
PPARD Q03181 2/20 0.38
CTSS P25774 5/20 0.37
CTSK P43235 4/20 0.37
CTSL P07711 1/20 0.37
CTSB P07858 1/20 0.37
ALDH1A1 P00352 1/20 0.37
TSHR P16473 1/20 0.37
IDO1 P14902 1/20 0.36
ITGA4 P13612 1/20 0.36
ITGB7 P26010 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3982451 1.00 PPARA (0.39) PPARAPPARGITGB3ITGA2BREN
SCHEMBL3980235 0.90 REN (0.36) RENMMP13CTSSCTSKCTSL
SCHEMBL3980233 0.90 REN (0.36) RENMMP13CTSSCTSKCTSL
SCHEMBL20502152 0.83 ITGB3 (0.47) PPARAPPARGITGB3ITGA2BREN
SCHEMBL21879135 0.83 ITGB3 (0.47) PPARAPPARGITGB3ITGA2BREN
SCHEMBL6095308 0.83 ITGB3 (0.47) PPARAPPARGITGB3ITGA2BREN
SCHEMBL3982449 0.78 MAPT (0.35) RENCTSSCTSKCTSLCTSB
SCHEMBL6630571 0.76 PPARA (0.57) PPARAPPARGACEMMP13PPARD
SCHEMBL6630572 0.76 PPARA (0.57) PPARAPPARGACEMMP13PPARD
SCHEMBL21946219 0.75 NLRP3 (0.44) RENCTSSCTSKCTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663958-B1 HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY INC (US) 2015-02-25 EP disclosed
US-7547701-B2 Haloalkyl containing compounds as cysteine protease inhibitors VIROBAY, INC. (US) 2009-06-16 US disclosed
EP-1663958-A2 HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2006-06-07 EP disclosed
US-20050182096-A1 Haloalkyl containing compounds as cysteine protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-08-18 US disclosed
WO-2005028429-A2 HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182096-A1 Haloalkyl containing compounds as cysteine protease inhibitors CTSF, CTSS, CTSE PPARA 2614/4885PPARG 3391/4885ITGB3 4115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.